Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
NeuroBo Pharmaceuticals Inc Market Cap
The NeuroBo Pharmaceuticals Inc (NRBO) share price is expected to increase by 945.75% over the next year. This is based on calculating the average 12-month share price estimate provided by 2 stock analysts who have covered NRBO. Price targets range from $10 at the low end to $48 at the high end. The current analyst consensus for NRBO is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
NRBO is a stock in Healthcare which has been forecasted to be worth $26.66667 as an average. On the higher end, the forecast price is $48 USD by from and on the lower end NRBO is forecasted to be $10 by Jason McCarthy from Maxim Group.
These are the latest 20 analyst ratings of NRBO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason McCarthy Maxim Group | Buy | $10 | Initiates | May 8, 2024 |
| Aydin Huseynov Ladenburg Thalmann | Buy | $6 | Initiates | Dec 7, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $16 | Maintains | Feb 1, 2021 |
HC Wainwright & Co. | Buy | Initiates | Jun 15, 2020 |
When did it IPO
2016
Staff Count
8
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Hyung-Heon Kim
Market Cap
$20.3M
In 2023, NRBO generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NRBO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - NeuroBo Pharmaceuticals, Inc. will change its name to MetaVia Inc. and adopt the new Nasdaq ticker symbol MTVA, effective November 29, 2024, ahead of key clinical milestones.
Why It Matters - The name change to MetaVia Inc. and the strategic realignment signal a potential shift in focus for NeuroBo Pharmaceuticals, which may affect investor confidence and future valuation.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - NeuroBo Pharmaceuticals (Nasdaq: NRBO) will participate in the Life Science Virtual Investor Forum on November 14, 2024, as part of its focus on cardiometabolic diseases.
Why It Matters - NeuroBo Pharmaceuticals' conference participation may signal potential investor interest and future funding opportunities, impacting stock performance and market perception of the company's growth prospects.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - NeuroBo Pharmaceuticals reported positive Phase 1 trial data for DA-1726 in obesity treatment, with $21.7M cash to fund operations into Q3 2025. Phase 2a results for DA-1241 expected December 2024.
Why It Matters - Positive trial results for DA-1726 signal potential for obesity treatment, boosting investor confidence. The cash position supports ongoing development, crucial for future growth and partnerships.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - NeuroBo Pharmaceuticals has completed the final patient visit in its Phase 2a trial for DA-1241, targeting metabolic dysfunction-associated steatohepatitis, with data expected in December 2024.
Why It Matters - The upcoming data readout in December 2024 for NeuroBo Pharmaceuticals' trial could significantly influence the company's stock price and investor sentiment based on treatment potential.
Mon, 30 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - NeuroBo Pharmaceuticals reported positive top-line data on safety and pharmacokinetics for DA-1726, a treatment for obesity. Phase 1 Part 3 to assess early proof of concept is planned for Q1 2025.
Why It Matters - Positive trial data for NeuroBo's DA-1726 indicates potential for effective obesity treatment, enhancing investor confidence in the company's prospects and future valuations.
Tue, 01 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - NeuroBo Pharmaceuticals (Nasdaq: NRBO) will participate in investor conferences on October 7, 2024, focused on cardiometabolic diseases.
Why It Matters - NeuroBo Pharmaceuticals' participation in investor conferences can attract interest, potentially boost stock liquidity, and signal progress in their cardiometabolic research, influencing investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
